Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial.

EBioMedicine · 2015 · PMC4703720 · PMID 26844270

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significanceP = 0.09so close (0.05 < p ≤ 0.1)

In contrast, maximal CMAP was reduced by 39 ± 11% compared to baseline in the placebo-treated group and only by 14 ± 8% in the flecainide group, although this difference did not reach statistical significance (P = 0.09; Fig. 4 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.